Legal & General Group Plc purchased a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 88,640 shares of the company’s stock, valued at approximately $2,249,000. Legal & General Group Plc owned about 0.22% of Pacira BioSciences at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in Pacira BioSciences by 0.5% during the third quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company’s stock worth $55,751,000 after acquiring an additional 11,831 shares during the last quarter. Balyasny Asset Management L.P. lifted its stake in shares of Pacira BioSciences by 36.1% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock worth $50,925,000 after purchasing an additional 565,288 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock worth $27,454,000 after purchasing an additional 367,869 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Pacira BioSciences by 7.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 676,352 shares of the company’s stock valued at $17,504,000 after purchasing an additional 49,079 shares during the period. Finally, Invesco Ltd. increased its stake in Pacira BioSciences by 7.9% in the third quarter. Invesco Ltd. now owns 517,424 shares of the company’s stock valued at $13,334,000 after purchasing an additional 38,025 shares during the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Pacira BioSciences
In other news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $23.50, for a total value of $143,702.50. Following the completion of the sale, the senior vice president owned 62,284 shares of the company’s stock, valued at $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $23.23, for a total value of $70,619.20. Following the completion of the sale, the insider owned 216,384 shares of the company’s stock, valued at approximately $5,026,600.32. This trade represents a 1.39% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.
Pacira BioSciences Price Performance
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. The company had revenue of $192.40 million for the quarter, compared to the consensus estimate of $191.06 million. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business posted $0.74 EPS. As a group, research analysts predict that Pacira BioSciences, Inc. will post 1.98 EPS for the current year.
Analyst Ratings Changes
PCRX has been the subject of several recent analyst reports. Truist Financial assumed coverage on Pacira BioSciences in a report on Monday, August 17th. They issued a “buy” rating and a $30.00 price target for the company. Needham & Company LLC increased their price objective on shares of Pacira BioSciences from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings raised shares of Pacira BioSciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. Wall Street Zen downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $30.20.
View Our Latest Stock Report on Pacira BioSciences
Pacira BioSciences Company Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Stories
- Five stocks we like better than Pacira BioSciences
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
